肝脏免疫炎症在非酒精性脂肪性肝病发生发展中的作用

祝娟娟; 程明亮; 赵雪珂

doi:10.3969/j.issn.1001-5256.2016.03.038

肝脏免疫炎症在非酒精性脂肪性肝病发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2016.03.038

贵州医科大学附属医院感染科

基金项目:

国家自然科学基金(81560100)；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 1474
- HTML全文浏览量: 35
- PDF下载量: 414
- 被引次数: 0
出版历程
- 出版日期: 2016-03-20

Role of liver immunological inflammation in development and progression of nonalcoholic fatty liver disease

Department of Infectious Diseases, The Affiliated Hospital of Guizhou Medical University

Research funding:

摘要

摘要:
非酒精性脂肪性肝病(NAFLD)是临床上常见的肝脏疾病之一,其发病机制较为复杂,"二、三次打击"学说仍是目前得到公认的NAFLD的主要发病机制。但近年来,肝脏免疫炎症在NAFLD的发生、发展中逐步得到众多研究者的重视。从肝脏免疫炎症的角度,阐述了肝脏免疫炎症导致NAFLD发生、发展的机制。
- 脂肪肝 /
- 免疫 /
- 炎症 /
- 综述
Abstract:
Non- alcoholic fatty liver disease( NAFLD) is a common liver disease in clinical practice and has a complex pathogenesis. At present,the " two- or three- hit" theory is still widely acknowledged as the major pathogenesis of NAFLD. However,in recent years,the role of liver immunological inflammation in the development and progression of NAFLD has been taken more and more seriously. This article elaborates on the mechanism of liver immunological inflammation in the development and progression of NAFLD from the perspective of liver immunological inflammation.
- fatty liver /
- immunity /
- inflammation /
- review

HTML全文

参考文献(38)

[1]LOOMBA R,SANYAL AJ.The global NAFLD epidemic[J].Nat Rev Gastroenterol Hepatol,2013,10(11):686-690.

[2]YEH MM,BRUNT EM.Pathological features of fatty liver disease[J].Gastroenterology,2014,147(4):754-764.

[3]de MINICIS S,DAY C,SVEGLIATI-BARONI G.From NAFLD to NASH and HCC:pathogenetic mechanisms and therapeutic insights[J].Curr Pharm Des,2013,19(29):5239-5249.

[4]DOWMAN JK,TOMLINSON JW,NEWSOME PN.Systematic review:the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J].Aliment Pharmacol Ther,2011,33(5):525-540.

[5]AHMED M.Non-alcoholic fatty liver disease in 2015[J].World J Hepatol,2015,7(11):1450-1459.

[6]ONIKI K,SARUWATARI J,IZUKA T,et al.Influence of the PNPLA3 rs738409 polymorphism on non-alcoholic fatty liver disease and renal function among normal weight subjects[J].PLo S One,2015,10(7):132640.

[7]DIXON LJ,BARNES M,TANG H,et al.Kupffer cells in the liver[J].Compr Physiol,2013,3(2):785-797.

[8]LESTER SN,LI K.Toll-like receptors in antiviral innate immunity[J].J Mol Biol,2014,426(6):1246-1264.

[9]AVBELJ M,WOLZ OO,FEKONJA O,et al.Activation ol lymphoma-associated My D88 mutations via allostery induced TIR-domain oligomerization[J].Blood,2014,124(26):3896-3904.

[10]WANG H,LAFDIL F,KONG X,et al.Signal transducer and activator of transcription 3 in liver diseases:a novel therapeutic target[J].Int J Biol,2011,7(5):536-550.

[11]BIEGHS V,TRAUTWEIN C.Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease[J].Hepatobiliary Surg Nutr,2014,3(6):377-385.

[12]MEDVEDEV AE.Toll-like receptor polymorphisms,inflammatory and infectious diseases,allergies,and cancer[J].J Interferon Cytokine Res,2013,33(9):467-484.

[13]RAMADORI P,KROY D,STREETZ KL.Immunoregulation by lipids during the development of non-alcoholic steatohepatitis[J].Hepatobiliary Surg Nutr,2015,4(1):11-23.

[14]LIU M,GUO S,HIBBERT JM,et al.CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications[J].Cytokine Growth Factor Rev,2011,22(3):121-130.

[15]IYER SS,CHENG G.Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease[J].Crit Rev Immunol,2012,32(1):23-63.

[16]ZHANG X,SHEN J,MAN K,et al.CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of nonalcoholic steatohepatitis[J].J Hepatol,2014,61(6):1365-1375.

[17]SABAT R,GRTZ G,WARSZAWSKA K,et al.Biology of interleukin-10[J].Cytokine Growth Factor Rev,2010,21(5):331-344.

[18]RYAN JJ,KASHYAP M,BAILEY D,et al.Mast cell bomeostasis:a fundamental aspect of allergic disease[J].Crit Rev Immunol,2007,27(1):15-32.

[19]GU QP,BAI AP.Interleukin-10 and inflammatory bowel disease[J].World Chin J Dig,2011,19(1):57-61.(in Chinese)顾秋萍,白爱平.白介素-10与炎症性肠病[J].世界华人消化杂志,2011,19(1):57-61.

[20]QING Q,ZHOU DS.The variation and significance of serum ratio of IL-18 and IL-10 in NAFLD rats[J].Acta Univ Med Anhui,2013,48(9):1041-1043.(in Chinese)秦清,周冬生.非酒精性脂肪性肝病大鼠血清白介素18、白介素10及其比值的变化和意义[J].安徽医科大学学报,2013,48(9):1041-1043.

[21]HOLAN V,ZAJICOVA A,JAVORKOVA E,et al.Distinct cytokines balance the development of regulatory T cells and interleukin-10-producing regulatory B cells[J].Immunology,2014,141(4):577-586.

[22]KONG X,FENG D,MATHEWS S,et al.Hepatoprotective and antifibrotic functions of interleukin-22:therapeutic potential for the treatment of alcoholic liver disease[J].J Gastroenterol Hepatol,2013,28(Suppl 1):56-60.

[23]GAO B,JEONG WI,TIAN Z.Liver:an organ with predominant innate immumity[J].Hepotology,2008,47(2):729-736.

[24]GAO B,RADAEVA S,PARK O.Liver natural killer and natural killer T cells:immunobiology and emerging roles in liver diseases[J].J Leukoc Biol,86(3):513-528.

[25]ADLER M,TAYLOR S,CKEBUGEU K,et al.Intrahepatic natural killer T cell populations are increased in human hepatic steatosis[J].World J Gastroenterol,2011,17(13):1725-1731.

[26]MAHER JJ,LEON P,RYAN JC.Beyond insulin resistance:innate immunity in non-alcoholic steatohepatitis[J].Hepatology,2008,48(2):670-678.

[27]ELINAV E,PAPPO O,SKLAIR-LEVY M,et al.Amelioration of non-alcoholic steatohepatitis and glucose intolerance in ob/ob mice by oral immune regulation towards liver-extracted proteins is associated with elevated intrahepatic NKT lymphocytes and serum IL-10 levels[J].J Pathol,2006,208(1):74-81.

[28]TANG T,SUI Y,LIAN M,et al.Pro-Inflammatory activated Kupffer cells by lipids induce hepatic NKT cells deficiency through activation-Induced cell death[J].PLo S One,2013,8(12):81949.

[29]COOL N,PONSAERTS P,van TENDELOO VF,et al.Regulatory T cells and human disease[J].Clin Dev Immunol,2007:89195.

[30]ROBERTSON FC,BERZOFSKY JA,TERABE M.NKT cell networks in the regulation of tumor immunity[J].Front Immunol,2014,5:543.

[31]GUO Y,LI W,YE AZ,et al.Study on chemotaxis of regulatory T cells induced by different antigents in mice[J].Chin J Immunol,2015,31(8):1032-1036.(in Chinese)郭音,李伟,叶艾竹,等.不同抗原诱导后小鼠调节性T淋巴细胞趋化特性动态研究[J].中国免疫学杂志,2015,31(8):1032-1036.

[32]VONGHIA L,MICHIELSEN P,FRANCQUE S.Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis[J].Int J Mol Sci,2013,14(10):19867-19890.

[33]CIPOLLETTA D,FEUERER M,LI A,et al.PPAR-γis a major driver of the accumulation and phenotype of adipose tissue Treg cells[J].Nature,2012,486(7404):549-553.

[34]ILAN Y.Immune therapy for non-alcoholic steatohepatitis:are we there yet?[J].J Clin Gastroenterol,2013,47(4):298-307.

[35]ZHOU LL.The expression of Th 17 related with cytokine in NAFLD[D].Fujian Med Univ,2014.(in Chinese).周丽丽.Th17细胞及相关细胞因子在非酒精性脂肪肝模型中的表达[D].福建医科大学,2014.

[36]SUTTI S,JINDAL A,LOCATELLI I,et al.Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH[J].Hepatology,2014,59(3):886-897.

[37]TANG Y,BIAN Z,ZHAO L,et al.Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease[J].Clin Exp Immunol,2011,166(2):281-290.

[38]MARINONI B,CERIBELLI A,MASSAROTTI MS,et al.The Th17 axis in poriatic disease:pathogenetic and therapeutic implications[J].Auto Immun Highlights,5(1):9-19.

施引文献

资源附件(0)

访问统计